Measurable residual disease results after consolidation therapy predictive of relapse in pediatric leukemia

For children with acute lymphoblastic leukemia (ALL), measurable residual disease (MRD) after the end of first consolidation (EOC) can be used to predict the need for subsequent MRD measurements, according to a study published online Sept. 10 in Leukemia.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup